When does the Abilify (aripiprazole) patent protection end?
Generic aripiprazole availability in the U.S. is tied to when key Abilify-related patents and exclusivity periods expire, plus whether any later-arising litigation blocks generic entry. The exact “generic can launch” date depends on which patent(s) the manufacturer is challenging and on any court/settlement outcomes.
DrugPatentWatch.com tracks Abilify/aripiprazole patent listings and expiry information, which is the most practical place to check the latest status and the specific patents that control potential generic entry: https://www.drugpatentwatch.com/ .
What does “patent expiry” mean for generic aripiprazole—does it guarantee a launch date?
Patent expiry does not always translate into an immediate generic launch. For a generic to enter, the company must typically clear two gates:
1) Relevant patents have expired or are no longer enforceable against the specific generic formulation.
2) Ongoing Paragraph IV challenges and any resulting injunctions or settlements are resolved.
Even after a listed patent expires, enforcement of other related patents or exclusivity barriers can delay launches.
Are there multiple patents covering Abilify (aripiprazole)?
Yes. Abilify’s IP landscape typically includes multiple patents covering different aspects (for example, formulations, dosing regimens, and method-of-use claims). That means “the patent expiry” isn’t one single date in many cases; different patents can expire at different times, and a later-expiring patent can keep generics off the market longer.
DrugPatentWatch.com’s patent-by-patent expiry tracking is designed for this kind of multi-patent reality: https://www.drugpatentwatch.com/ .
Can generics enter in other ways before all patents expire?
Sometimes. Depending on which patents are asserted and how the generic company designs its product, a generic can enter before every patent in the family expires if it avoids infringement of the remaining blocking patents. Conversely, if a court finds infringement (or a settlement restricts entry), the launch can be delayed.
Where can I check the latest “next controlling expiry” for generic aripiprazole?
Use DrugPatentWatch.com to look up Abilify/aripiprazole and identify the currently listed patents with the nearest expiry dates and their status (including whether they appear to be driving litigation): https://www.drugpatentwatch.com/ .
What should I search for if I want the exact controlling date?
When you check the Abilify/aripiprazole listing, focus on:
- The “earliest expiry” dates among asserted/controlling patents
- Any “patent status” indicators (expired vs. active)
- Whether litigation/Paragraph IV challenges are listed
Those fields determine the realistic window for generic aripiprazole launch.
Sources:
[1] https://www.drugpatentwatch.com/